IN2015DN00372A - - Google Patents
Info
- Publication number
- IN2015DN00372A IN2015DN00372A IN372DEN2015A IN2015DN00372A IN 2015DN00372 A IN2015DN00372 A IN 2015DN00372A IN 372DEN2015 A IN372DEN2015 A IN 372DEN2015A IN 2015DN00372 A IN2015DN00372 A IN 2015DN00372A
- Authority
- IN
- India
- Prior art keywords
- met
- synthesis
- treating
- formula
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012077924 | 2012-06-29 | ||
PCT/CN2013/078592 WO2014000713A1 (en) | 2012-06-29 | 2013-07-01 | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN00372A true IN2015DN00372A (de) | 2015-06-12 |
Family
ID=49782283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN372DEN2015 IN2015DN00372A (de) | 2012-06-29 | 2013-07-01 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9617257B2 (de) |
EP (1) | EP2867223B1 (de) |
JP (1) | JP6059342B2 (de) |
KR (3) | KR101726555B1 (de) |
AU (1) | AU2013283993B2 (de) |
BR (1) | BR112014032745B1 (de) |
CA (1) | CA2878049C (de) |
ES (1) | ES2698511T3 (de) |
HK (1) | HK1207642A1 (de) |
IN (1) | IN2015DN00372A (de) |
RU (1) | RU2619130C2 (de) |
SG (1) | SG11201408750VA (de) |
TW (1) | TWI520962B (de) |
WO (1) | WO2014000713A1 (de) |
ZA (1) | ZA201500344B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
AU2016297395B2 (en) * | 2015-07-20 | 2019-01-17 | Betta Pharmaceuticals Co., Ltd | Crystalline form of fused pyridine derivative's maleate and uses thereof |
CN108853108A (zh) * | 2015-12-31 | 2018-11-23 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
CN109071504B (zh) | 2016-02-05 | 2022-03-08 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
JP2021506735A (ja) * | 2017-05-26 | 2021-02-22 | イクノス サイエンシズ エスエー | 新規map4k1阻害剤 |
EP3643715A4 (de) * | 2017-06-19 | 2020-10-28 | Abbisko Therapeutics Co., Ltd. | Stickstoff-heteroaryl-derivat mit csf1r-hemmender wirkung und herstellungsverfahren dafür sowie anwendung davon |
CN109988108B (zh) * | 2017-12-29 | 2022-04-29 | 江苏豪森药业集团有限公司 | 一种卡博替尼的制备方法 |
AU2019395282A1 (en) * | 2018-12-14 | 2021-07-08 | Beta Pharma, Inc. | Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TWI812302B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Lg化學股份有限公司 | 作為ron抑制劑之新穎尿素衍生物化合物 |
EP4289427A1 (de) * | 2022-06-10 | 2023-12-13 | Anagenesis Biotechnologies | Dihydro[1,8]naphthyridin-7-one und pyrido[3,2-b][1,4]oxazin-3-one zur verwendung bei der behandlung von krebs und insbesondere von metastasen. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004255566B2 (en) * | 2003-07-07 | 2010-07-08 | Merk Patent Gmbh | Malonamide derivatives |
DE10357510A1 (de) * | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroarylsubstituierte Benzole |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7977345B2 (en) * | 2004-07-02 | 2011-07-12 | Exelixis, Inc. | c-MET modulators and method of use |
US7772247B2 (en) * | 2004-07-30 | 2010-08-10 | Methylgene Inc. | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor |
CA2587642C (en) * | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
AU2006313456B2 (en) | 2005-05-20 | 2011-06-23 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
JP2010507618A (ja) * | 2006-10-27 | 2010-03-11 | グラクソ グループ リミテッド | c−Metキナーゼ阻害薬としての7−アザインドール誘導体 |
US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
KR100961410B1 (ko) * | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
RU2011119478A (ru) * | 2008-10-14 | 2012-11-27 | Нин Си | Соединения и способы применения |
CN102086211B (zh) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | 作为蛋白激酶抑制剂的芳杂环化合物 |
JP5770281B2 (ja) * | 2010-07-14 | 2015-08-26 | ベータ ファーマシューティカルズ カンパニー リミテッド | c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体 |
-
2013
- 2013-06-29 TW TW102123415A patent/TWI520962B/zh not_active IP Right Cessation
- 2013-07-01 US US14/411,515 patent/US9617257B2/en active Active
- 2013-07-01 EP EP13809182.2A patent/EP2867223B1/de not_active Not-in-force
- 2013-07-01 AU AU2013283993A patent/AU2013283993B2/en not_active Ceased
- 2013-07-01 KR KR1020177003335A patent/KR101726555B1/ko active IP Right Grant
- 2013-07-01 KR KR1020157002238A patent/KR101726522B1/ko active IP Right Grant
- 2013-07-01 CA CA2878049A patent/CA2878049C/en not_active Expired - Fee Related
- 2013-07-01 JP JP2015518816A patent/JP6059342B2/ja not_active Expired - Fee Related
- 2013-07-01 KR KR1020177003331A patent/KR101770545B1/ko active IP Right Grant
- 2013-07-01 ES ES13809182T patent/ES2698511T3/es active Active
- 2013-07-01 RU RU2015102057A patent/RU2619130C2/ru active
- 2013-07-01 SG SG11201408750VA patent/SG11201408750VA/en unknown
- 2013-07-01 WO PCT/CN2013/078592 patent/WO2014000713A1/en active Application Filing
- 2013-07-01 IN IN372DEN2015 patent/IN2015DN00372A/en unknown
- 2013-07-01 BR BR112014032745-9A patent/BR112014032745B1/pt not_active IP Right Cessation
-
2015
- 2015-01-16 ZA ZA2015/00344A patent/ZA201500344B/en unknown
- 2015-08-27 HK HK15108314.5A patent/HK1207642A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2013283993B2 (en) | 2016-07-07 |
KR20170017015A (ko) | 2017-02-14 |
JP2015521634A (ja) | 2015-07-30 |
RU2619130C2 (ru) | 2017-05-12 |
EP2867223A4 (de) | 2016-01-06 |
JP6059342B2 (ja) | 2017-01-11 |
CA2878049A1 (en) | 2014-01-03 |
ZA201500344B (en) | 2016-08-31 |
AU2013283993A1 (en) | 2015-02-05 |
CA2878049C (en) | 2016-12-13 |
US20150315210A1 (en) | 2015-11-05 |
ES2698511T3 (es) | 2019-02-05 |
BR112014032745A2 (pt) | 2017-06-27 |
SG11201408750VA (en) | 2015-01-29 |
BR112014032745B1 (pt) | 2022-01-04 |
KR101726555B1 (ko) | 2017-04-12 |
RU2015102057A (ru) | 2016-08-20 |
KR20170017014A (ko) | 2017-02-14 |
US9617257B2 (en) | 2017-04-11 |
EP2867223A1 (de) | 2015-05-06 |
KR20150031320A (ko) | 2015-03-23 |
TWI520962B (zh) | 2016-02-11 |
KR101770545B1 (ko) | 2017-08-22 |
TW201418254A (zh) | 2014-05-16 |
EP2867223B1 (de) | 2018-09-05 |
WO2014000713A1 (en) | 2014-01-03 |
KR101726522B1 (ko) | 2017-04-12 |
HK1207642A1 (en) | 2016-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN00372A (de) | ||
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
PH12017502141A1 (en) | Compounds and their methods of use | |
GEP201706688B (en) | Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer | |
AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
PH12014502772A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
MX353299B (es) | Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer. | |
MX348451B (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12. | |
IN2015DN01151A (de) | ||
IN2014CN03072A (de) | ||
TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
CR20140528A (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1 | |
TN2013000420A1 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
CY1119470T1 (el) | Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη | |
MX2015012343A (es) | Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa. | |
IN2015DN00950A (de) | ||
IN2014DN08443A (de) | ||
IN2013MU01290A (de) | ||
MX2015005312A (es) | Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12. | |
MX337610B (es) | Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma. | |
MX371011B (es) | Intermediarios y métodos para sintetizar derivados de calicheamicina. | |
NZ743260A (en) | Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors |